Table 7.
Patient baseline characteristics for pregnant women exposed to mRNA COVID-19 vaccine and ending their pregnancy during pregnancy after 20 wks (population 2d).
| PREGNANCY OUTCOME ANALYSIS |
|||||
|---|---|---|---|---|---|
| n = 530 | |||||
| n | % | ||||
| Maternal age at first dose (years) | |||||
| <25 | 2 | 0.4 | % | ||
| 25-29 | 53 | 10.0 | % | ||
| 30-34 | 224 | 42.3 | % | ||
| 35-39 | 178 | 33.6 | % | ||
| ≥40 | 32 | 6.0 | % | ||
| Missing | 41 | 7.7 | |||
| Swiss linguistic area | |||||
| German | 344 | 64.9 | % | ||
| French | 179 | 33.8 | % | ||
| Italian | 7 | 1.3 | % | ||
| Maternal medical condition | 108 | 20.4 | % | ||
| Pulmonary comorbidities | 11 | 2.1 | % | ||
| Cardiac comorbidities | 20 | 3.8 | % | ||
| Hypertension | 7 | 1.3 | % | ||
| Pre-gestational diabetes | 4 | 0.8 | % | ||
| Obesity (BMI >30kg/m2) | 28 | 5.3 | % | ||
| Immunosuppression | 3 | 0.6 | % | ||
| Auto-immune diseases | 7 | 1.3 | % | ||
| Hematologic comorbidities | 3 | 0.6 | % | ||
| Neurological comorbidities | 1 | 0.2 | % | ||
| Digestive comorbidities | 3 | 0.6 | % | ||
| Renal comorbidities | 4 | 0.8 | % | ||
| Urological comorbidities | 1 | 0.2 | % | ||
| Oncological comorbidities | 1 | 0.2 | % | ||
| Thyroid dysfunction | 33 | 6.2 | % | ||
| Psychiatric disorders | 6 | 1.1 | % | ||
| Other | 9 | 1.7 | % | ||
| Pregnancy | |||||
| Nulliparous | 220 | 41.5 | % | ||
| Twin pregnancy | 5 | 0.9 | % | ||
| Previous caesarean section | 77 | 14.5 | % | ||
| EXPOSURE | |||||
| Type of vaccine | |||||
| Pfizer/BioNTech - BNT162b2 | 150 | 28.3 | % | ||
| Moderna - mRNA-1273 | 380 | 71.7 | % | ||
| 1st dose of vaccine | |||||
| Trimester of injection | |||||
| Peri-conception (7 days before LMP to 13 days after LMP) | 0 | - | |||
| T1 - 14 days after LMP and <12 wks | 2 | 0.4 | % | ||
| T2 - ≥12 and <28 wks | 303 | 57.2 | % | ||
| T3 - ≥28 wks | 225 | 42.5 | % | ||
| Place of vaccination | |||||
| Vaccination centre / Health authority | 177 | 33.4 | % | ||
| Gynaecologist / Midwife consultation (PRIVATE PRACTICE) | 1 | 0.2 | |||
| Gynaecologist / Midwife consultation (HOSPITAL) | 11 | 2.1 | % | ||
| GP (General practitioner) | 5 | 0.9 | % | ||
| Occupational health service (at work) | 8 | 1.5 | % | ||
| Pharmacist | 8 | 1.5 | % | ||
| Unknown | 4 | 0.8 | % | ||
| Missing | 316 | 59.6 | % | ||
| Injection site | |||||
| Left arm | 171 | 32.3 | % | ||
| Right arm | 32 | 6.0 | % | ||
| Missing | 327 | 61.7 | % | ||
| Antipyretic intake around injection | |||||
| Yes | 22 | 4.2 | % | ||
| No | 180 | 34.0 | % | ||
| Unknown | 7 | 1.3 | % | ||
| Missing | 321 | 60.6 | % | ||
| 2nd dose of vaccine | |||||
| - During pregnancy | 456 | 86.0 | % | ||
| Trimester of injection | |||||
| Peri-conception (7 days before LMP to 13 days after LMP) | 0 | - | |||
| T1 - 14 days after LMP and <12 wks | 0 | - | |||
| T2 - ≥12 and <28 wks | 174 | 32.8 | % | ||
| T3 - ≥28 wks | 282 | 53.2 | % | ||
| Place of vaccination | |||||
| Vaccination centre / Health authority | 154 | 29.1 | % | ||
| Gynaecologist / Midwife consultation (PRIVATE PRACTICE) | 1 | 0.2 | |||
| Gynaecologist / Midwife consultation (HOSPITAL) | 8 | 1.5 | % | ||
| GP (General practitioner) | 4 | 0.8 | % | ||
| Occupational health service (at work) | 6 | 1.1 | % | ||
| Pharmacist | 7 | 1.3 | % | ||
| Unknown | 3 | 0.6 | % | ||
| Missing | 273 | 51.5 | % | ||
| Injection site | |||||
| Left arm | 153 | 28.9 | % | ||
| Right arm | 33 | 6.2 | % | ||
| Missing | 298 | 56.2 | % | ||
| Antipyretic intake around injection | |||||
| Yes | 31 | 5.8 | % | ||
| No | 168 | 31.7 | % | ||
| Unknown | 6 | 1.1 | % | ||
| Missing | 279 | 52.6 | % | ||
T1-3: trimester 1-3.
LMP: last menstrual period.
wks: weeks of gestation.